Drugs / CG200745
CG200745
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05716919 | Mar → Dec 2023 | cancer, hematopoietic and lymphoid cell neoplasm | Machaon Biotherapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05345912 | Dec 2019 → Sep 2020 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01226407 | Sep 2010 → Feb 2013 | cancer | CrystalGenomics, Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05249101 | Aug 2022 → Jun 2026 overdue | pancreatic adenocarcinoma | CG Pharmaceuticals, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG200745 | “Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule” NCT05716919 ↗ |
| Known as | CG 2 (HDAC INHIBITOR) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297366 ↗ |
| Known as | CG-745 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05345912 ↗ |
| Known as | HDCG-0745 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297366 ↗ |
| Known as | Ivaltinostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05716919 ↗ |
| Known as | J3.106.463E | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297366 ↗ |
| Action | Inhibit | “inhibits enzymatic activity of histone deacetylase (HDAC).” NCT05249101 ↗ |
| Modality | Small molecule | — CHEMBL4297366 ↗ |
| Route | Intravenous | “Multiple administration (IV) over the cycles untile MTD/LTD” NCT01226407 ↗ |